Anti-BCMA CAR-NK Cell Therapy for the Relapsed or Refractory Multiple Myeloma

NCT05008536 · clinicaltrials.gov ↗

EARLY_PHASE1

Phase

UNKNOWN

Status

27

Enrollment

OTHER

Sponsor class

Conditions

Multiple Myeloma, Refractory

Interventions

BIOLOGICAL: Anti-BCMA CAR-NK Cells
DRUG: Fludarabine
DRUG: Cytoxan

Sponsor

Xinqiao Hospital of Chongqing

Collaborators

[object Object]